The New York Times' Shannon Brownlee and Jeanne Lenzer discuss physicians' "polarized views about the logic of routine testing" for cancers, particularly in light of the recent debates over the utility of prostate-specific antigen testing. "The dueling narratives of PSA testing boil down to the way each side frames the potential for harm from the disease compared with the collateral damage from the test and subsequent treatment," Brownlee and Lenzer write.
To Test? To Treat?
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.